Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Linagliptin Bioavailability in Healthy Volunteers
NCT02172222Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state at 8 days and Maximum measured concentration at steady state at 8 days. Started Jul 2009; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172222.